Similarly, in autoimmune and allergic diseases that are CD4+ T cell–dependent, T-helper polarization, or in MHC class II–restricted diseases, SDHA inhibition could mitigate autoimmune/allergic disorders. Here, CD4 is linked to allergic disease.